These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 32360983)

  • 1. Association of Daily Aspirin Therapy With Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis C Virus Infection.
    Lee TY; Hsu YC; Tseng HC; Lin JT; Wu MS; Wu CY
    Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2784-2792.e7. PubMed ID: 32360983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
    Lee TY; Hsu YC; Tseng HC; Yu SH; Lin JT; Wu MS; Wu CY
    JAMA Intern Med; 2019 May; 179(5):633-640. PubMed ID: 30882847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study.
    Liao YH; Hsu RJ; Wang TH; Wu CT; Huang SY; Hsu CY; Su YC; Hsu WL; Liu DW
    BMC Gastroenterol; 2020 Jan; 20(1):6. PubMed ID: 31918672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
    Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients.
    Hsu CS; Huang CJ; Kao JH; Lin HH; Chao YC; Fan YC; Tsai PS
    PLoS One; 2013; 8(7):e70458. PubMed ID: 23894660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
    Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection.
    Wu CY; Chen YJ; Ho HJ; Hsu YC; Kuo KN; Wu MS; Lin JT
    JAMA; 2012 Nov; 308(18):1906-14. PubMed ID: 23162861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study.
    Wu CY; Lin JT; Ho HJ; Su CW; Lee TY; Wang SY; Wu C; Wu JC
    Gastroenterology; 2014 Jul; 147(1):143-151.e5. PubMed ID: 24704525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.
    Park H; Wang W; Henry L; Nelson DR
    Hepatology; 2019 Mar; 69(3):1032-1045. PubMed ID: 30289989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
    J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
    Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
    Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
    Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E;
    Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma.
    Hsu YC; Ho HJ; Wu MS; Lin JT; Wu CY
    Hepatology; 2013 Jul; 58(1):150-7. PubMed ID: 23389758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis.
    Jang H; Lee YB; Moon H; Chung JW; Nam JY; Cho EJ; Lee JH; Yu SJ; Kim YJ; Lee J; Yoon JH
    Hepatology; 2022 Aug; 76(2):492-501. PubMed ID: 35100447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk.
    Darvishian M; Janjua NZ; Chong M; Cook D; Samji H; Butt ZA; Yu A; Alvarez M; Yoshida E; Ramji A; Wong J; Woods R; Tyndall M; Krajden M
    J Viral Hepat; 2018 Dec; 25(12):1481-1492. PubMed ID: 30047609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Nucleos(t)ide Analogue Therapy on Risk of Intrahepatic Cholangiocarcinoma in Patients With Chronic Hepatitis B.
    Lee TY; Hsu YC; Yu SH; Lin JT; Wu MS; Wu CY
    Clin Gastroenterol Hepatol; 2018 Jun; 16(6):947-954.e4. PubMed ID: 28951229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.
    Singer AW; Reddy KR; Telep LE; Osinusi AO; Brainard DM; Buti M; Chokkalingam AP
    Aliment Pharmacol Ther; 2018 May; 47(9):1278-1287. PubMed ID: 29516535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Indication of Aspirin Associated With Reduced Risk of Liver Cancer in Chronic Hepatitis B: A Nationwide Cohort Study.
    Yun B; Ahn SH; Yoon JH; Kim BK
    Am J Gastroenterol; 2022 May; 117(5):758-768. PubMed ID: 35294425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort).
    Hsu WF; Tsai PC; Chen CY; Tseng KC; Lai HC; Kuo HT; Hung CH; Tung SY; Wang JH; Chen JJ; Lee PL; Chien RN; Lin CY; Yang CC; Lo GH; Tai CM; Lin CW; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Su WW; Chu CH; Chen CJ; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Huang JF; Dai CY; Chuang WL; Yu ML; Peng CY
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2884-2892. PubMed ID: 33963615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.